echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > AstraZeneca's CLL drug Calquence is approved by NICE in the UK

    AstraZeneca's CLL drug Calquence is approved by NICE in the UK

    • Last Update: 2021-03-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationFan Dongdong

    A few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
    The drug has thus become the first targeted oral therapy for British patients with chronic lymphocytic leukemia (CLL) who cannot be treated with first-line chemotherapy.

    According to the draft recommendation guidelines issued by the British regulatory agency, the drug has been approved in December last year for the treatment of CLL patients with 17p deletion or TP53 mutation, or fludarabine combined with cyclophosphamide and rituximab (FCR), and bendumustine combined with rituximab (BR).
    Applicable CLL patients.
    Experts participating in the NICE Drug Advisory Committee also emphasized that Calquence is well tolerated and has fewer side effects compared with current CLL treatments.

    Calquence's NICE recommendation in the United Kingdom will provide this type of patient with a new treatment option other than chemotherapy, which is especially helpful during the COVID-19 pandemic.
    Patients affected by this epidemic are usually inconvenient to go to the hospital often.
    .
    The current known situation is that the price of a box of 100 mg Calquence tablets for 30 days is £5,059 (approximately RMB 45,766), but AstraZeneca will finally sell the drug to the British NHS at a discount on this basis.
    .

    In November last year, the European Medicines Agency (EMA) approved Calquence as a monotherapy or in combination with Roche Gazyvaro (obinutuzumab) for previously untreated and relapsed or refractory CLL patients.
    Britain’s NICE said, “Because the company did not submit any data on this combination, it did not make recommendations on the comparative effects of acalabrutinib and obinutuzumab.

    Reference source:

    1.
    NICE backs AstraZeneca's Calquence for CLL

    2.
    NICE backs AZ's Calquence for new use in leukaemia

    3.
    NICE backs AstraZeneca's Calquence for CLL

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.